Related Experiment Video

Updated: Mar 17, 2026

Assessing Gastrointestinal Motility in Caenorhabditis elegans RAC1/CED-10 Mutants as a Tool to Study Early Parkinson's Disease
05:17

Assessing Gastrointestinal Motility in Caenorhabditis elegans RAC1/CED-10 Mutants as a Tool to Study Early Parkinson's Disease

Published on: November 28, 2025

439

Nocardia asteroides-Induced movement abnormalities in mice: Relevance for Parkinson's disease?

David A Loeffler1, Peter A LeWitt2,3, Dianne M Camp4

  • 1Department of Neurology, Beaumont Hospital-Royal Oak, Beaumont Health, Royal Oak, Michigan, USA.

Movement Disorders : Official Journal of the Movement Disorder Society
|July 15, 2016
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

19.2K
Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
10:32

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

56.5K

Related Experiment Videos

Last Updated: Mar 17, 2026

Assessing Gastrointestinal Motility in Caenorhabditis elegans RAC1/CED-10 Mutants as a Tool to Study Early Parkinson's Disease
05:17

Assessing Gastrointestinal Motility in Caenorhabditis elegans RAC1/CED-10 Mutants as a Tool to Study Early Parkinson's Disease

Published on: November 28, 2025

439
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
05:38

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model

Published on: January 7, 2019

19.2K
Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
10:32

Assessment of Sensorimotor Function in Mouse Models of Parkinson's Disease

Published on: June 17, 2013

56.5K

Related Concept Videos

Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

1.3K
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
1.3K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

2.3K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
2.3K

Articles linked to this work by shared authors, journal, and citation graph.

Impaired olfaction and Parkinsonism: A "hidden gem" in the neurological literature.

Journal of Parkinson's disease·2026

Parkinsonism induced by carbon monoxide intoxication: A "hidden gem" in the neurological literature.

Journal of Parkinson's disease·2026

Chronic α-Synuclein Over-Expression and Ceruloplasmin Challenge Promote Distinct Iron and Redox Responses in M17 Cells.

bioRxiv : the preprint server for biology·2026

Opicapone Improves the Pharmacokinetics of Levodopa Administered as Extended-Release Capsules.

Clinical neuropharmacology·2026

Opicapone in Parkinson's patients with motor fluctuations: clinical assessments and patient-reported outcomes from the OPTI-ON study.

Clinical parkinsonism & related disorders·2026

Oxybutynin treatment for episodic hyperhidrosis in Parkinson disease.

Journal of Parkinson's disease·2026

Selectivity Filter KCND3 Variant Causes Spinocerebellar Ataxia 19/22 and KV4.3 Functional Loss.

Movement disorders : official journal of the Movement Disorder Society·2026

Longitudinal Iron Changes in the Substantia Nigra of Early-Stage Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

Spatiotemporal Tau Accumulation and its Clinical Impact on Progressive Supranuclear Palsy: Longitudinal Florzolotau (18F) Positron Emission Tomography.

Movement disorders : official journal of the Movement Disorder Society·2026

Distinct Spatiotemporal Patterns of Dopaminergic and Metabolic Imaging in De Novo Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

Fifteen-Year Outcomes of Bilateral Pallidal Stimulation in Isolated Generalized Dystonia: Characterization of Therapeutic Response and Emergence of Parkinsonism.

Movement disorders : official journal of the Movement Disorder Society·2026

Dopamine-Deficiency-Related Reorganization of the Somatomotor Network in Prodromal and Early Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026

Coxiella burnetii establishes a small cell variant (SCV)-like persistent form to survive adverse intracellular conditions.

Virulence·2026

Repeated emergence and fitness heterogeneity of KPC-33 in ST11 Klebsiella pneumoniae under ceftazidime-avibactam pressure.

Antimicrobial agents and chemotherapy·2026

Diagnostic Yield of Brain MRI in Pediatric Short Stature: Hypothalamic-Pituitary Lesions and Incidental Findings in Real-World Practice.

Clinical endocrinology·2026

Discovery of Highly Selective Noncovalent Macrocyclic Peptide Inhibitors Suppressing Both TMPRSS2 Protease Activity and Viral Receptor Function.

Journal of medicinal chemistry·2026

Gut microbiome and metabolite profiles are associated with subsequent histologic MASH in a longitudinal mouse model.

mSystems·2026

Anti-psychotic drugs act synergistically in combination with antifungal drugs to inhibit drug-resistant Cryptococcus neoformans and Candida albicans.

mSphere·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us